27
ALL2
Arbor Pharmaceuticals2
Aytu BioPharma1
Glenmark Pharmaceuticals2
Granules India Limited1
GRI Bio1
Lupin Ltd1
Medomie5
Noven Pharmaceuticals5
Tris Pharma Inc7
Vallon PharmaceuticalsYear
27
ALL2
20246
20238
20225
20216
2020DEALS // DEV.
27
ALL7
Deals20
DevelopmentsCountry
26
ALL3
INDIA1
ISRAEL22
U.S.A27
ALL1
Aardvark Therapeutics1
Aytu BioPharma1
Cediprof1
Lupin Pharma Canada20
Not Applicable1
Pediatrix Therapeutics1
Perigon Pharmacy 3601
UndisclosedTherapeutic Area
27
ALL25
Psychiatry/Psychology2
TechnologyStudy Phase
27
ALL15
Approved2
Phase III2
Phase II8
Phase IDeal Type
7
ALL4
Agreement2
Partnership1
Public OfferingProduct Type
27
ALL27
Small moleculeDosage Form
22
ALL2
Capsule1
Capsule, Extended Release1
Extended Release Tablet1
Extended-release tablet1
Immediate Release Tablet1
Immediate Release Tablets1
Immediate-Release Tablet1
Intranasal1
Oral3
Patch1
Tablet5
Tablet, Extended Release2
Transdermal1
immediate release tabletLead Product
27
ALL24
Amphetamine3
Dextroamphetamine SaccharateTarget
9
ALL1
CNS8
VMATLead Product(s) : Amphetamine,Dextroamphetamine Saccharate,Amphetamine Aspartate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Granules Pharmaceuticals Inc., Receives ANDA Approval for Amphetamine Mixed Salts ER Capsules
Details : Dextroamphetamine Sulfate is a non-catecholamine sympathomimetic amines with CNS stimulant activity. It is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extr...
Brand Name : Amphetamine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 24, 2023
Lead Product(s) : Amphetamine,Dextroamphetamine Saccharate,Amphetamine Aspartate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Granules Pharmaceuticals Receives ANDA Approval for Amphetamine Mixed Salts (IR Tablets)
Details : FDA approved generic of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, for Attention Deficit Hyperactivity Disorder and Narcolepsy.
Brand Name : Adderall-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 30, 2021
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Receives FDA Approval for Generic Version of Adderall XR
Details : Adderall XR-Generic is a combination product of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate & amphetamine sulfate. It is indicated for ADHD.
Brand Name : Adderall XR-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 21, 2024
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Lupin Pharma Canada
Deal Size : Undisclosed
Deal Type : Agreement
Aytu BioPharma Partners with Lupin Canada For ADHD Drug Commercialization
Details : The agreement aims for the distribution and supply for Aytu's Adzenys XR-ODT and Cotempla XR-ODT product lines for the treatment of ADHD in Canada.
Brand Name : Adzenys XR-ODT
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 01, 2024
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Lupin Pharma Canada
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Perigon Pharmacy 360
Deal Size : Undisclosed
Deal Type : Partnership
Details : Tris Pharma and Perigon launched a direct-to-patient program, that allows patients and caregivers access to DYANAVEL XR (amphetamine) extended-release tablets through Perigon’s digital pharmacy and receive assistance and support to help navigate their ...
Brand Name : Dyanavel XR
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 30, 2023
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Perigon Pharmacy 360
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Aardvark Therapeutics
Deal Size : $80.0 million
Deal Type : Agreement
Details : Under the agreement, Aardvark will acquire certain assets and intellectual property of the Company that pertain to ADAIR, a proprietary abuse-deterrent formulation of immediate release dextroamphetamine, for the development of certain follow-on pipeline ...
Brand Name : ADAIR
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 23, 2023
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Aardvark Therapeutics
Deal Size : $80.0 million
Deal Type : Agreement
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Aytu BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Medomie will commercialize Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) in Israel and the Palestinian Authority.
Brand Name : Adzenys XR
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 31, 2023
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Aytu BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Cediprof
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Glenmark will distribute Cediprof's FDA approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), the generic version...
Brand Name : Adderall-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 09, 2023
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Cediprof
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Xelstrym™ (dextroamphetamine) is a first and only FDA-approved, once-daily central nervous system stimulant transdermal patch for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
Brand Name : Xelstrym
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2023
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Pediatrix Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Dyanavel XR oral suspension (amphetamine) is a CNS stimulant that affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control used for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years a...
Brand Name : Dyanavel XR
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 01, 2022
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Pediatrix Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?